January 5, 2021 Emergex Vaccines has signed a collaboration and development agreement with the Institute of Technology and Immunobiologicals of the Oswaldo Cruz Foundation in Brazil to develop a COVID-19 vaccine using Emergex s next-generation synthetic T-cell vaccine technology.
The U.K.-based biotechnology company Emergex develops synthetic set point vaccines that prime the T-cell immune response to address viral and bacterial infections.
Under the agreement, both parties will work together to advance immunotherapeutic programs, including a vaccine candidate for COVID-19, through regulatory pathways of the Brazilian National Health Service. Emergex will also support studies, including clinical trials, and to manufacture, market, promote, and distribute certain infectious diseases vaccines within the National Health Service of Brazil.